|Published (Last):||18 December 2007|
|PDF File Size:||10.66 Mb|
|ePub File Size:||3.49 Mb|
|Price:||Free* [*Free Regsitration Required]|
Cutaneous reactions to recoinbinant cytokine therapy. J Am Acad Dermatol ; 33 — Presse Med ; 30 — PubMed Google Scholar. Lupus like reaction to Interferon at the injection site: report of five cases. J Cutan Pathol ; 34 — Ann Dermatol Venereal ; — Google Scholar. Allergy of delayed type to recombinant interferon-alpha 2c. Contact Derm ; 20 — Localized interferon alfa-2b-induced alopecia. Arch Dermatol ; — Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alfa in an HIV-infected patient.
Eur J Dermatol ; 12 : 99— Skin necrosis with subsequent formation of squamous cell carcinoma after subcutaneous interferon beta injection. J Am Acad Dermatol ; 37 — Injection site vasculitis in a patient receiving interferon alfa for chronic hepatitis C. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma.
Dermatology ; — Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol ; — Telogen effluvium due to recombinant interferon-alpha 2b.
Alpha-interferon-induced hair discoloration. Straight hair associated with interferon alfa plus ribavirin in hepatitis C infection. Growth of eyebrow after alpha interferon administration Am. Am J Hematol ; 53 — CrossRef Google Scholar. The Raynaud phenomenom and interferon therapy. Ann Med Intern ; Digital vasculitis associated with interferon therapy.
Am J Med ; 92 — Alphainterferon therapy and cutaneous vascular lesions. Ann Intern Med ; — Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer ; 65 — Autoimmunity induced by interferon — a therapy for chronic viral hepatitis. Biomed Pharmacother ; 53 — Ann Med Interne ; — Psoriasis and alpha-interferon. Lancet ; 1 — A survey of adverses events in 11, patients with chronic viral hepatitis treated with alfa interferon.
J Hepatol ; 24 — Lichen planus and virus C hepatitis: disappearance of the lichen under interferon alfa therapy. Dermatology ; Severe lichen planus-like eruption induced by interferon-alpha therapy. Eur J Dermatol ; 5 — Oropharyngeal pemphigus in a patient with chronic hepatitis C during interferon alpha-2a therapy.
Eur J Gastroenterol Hepatol ; 13 — Long-term interferon-alpha therapy induces autoantibodies against epidermis. More on cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol ; 35 Gastroenterol Clin Biol ; 24 — Hurst EA, Mauro T. Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. Possible induction of systemic lupus erythematosus by interferon-a treatment in a patient with a malignant carcinoid tumor.
J Int Med ; — Cutaneous side effects associated with interleukin 2 administration for metastatic melanoma. J Am Acad Dermatol ; 28 — Cutaneous effects of granulocyte colony-stimulating factor in healthy volunteers. Eur J Dermatol ; 8 — Granulomatous dermatitis with enlarged histiocytes: a characteristic pattern of granulocyte colony-stimulating factor. Report of two cases and review of the literature. Thrombotic and necrotizing panniculitis associated with recombinant human granulocyte col ony-stimulating factor treatment.
Cutaneous reactions to granulocyte-monocyte colony-stimulating factor. Perez-Soler R, Saltz L. J Clin Oncol ; 23 — Segaert S, Van Custem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol ; 16 — Acneiform eruption induced by epidermal growth factor receptor inhibitor in patients with solid tumours.
Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C National Cancer Institute. Common terminology criteria for adverse events v3.
Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer ; 16 — Ann Dermatol Venereal ; :9S— Cetuximab induced acne. Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy. Successful treatment with oral isotretinoin of acneiform skin lesion associated with cetuximab therapy.
Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Severe purpuric xerotic dermatitis associated with gefitinib therapy. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab.
Trichomegaly following treatment with gefitinib ZD Cutaneous side effects in non-small cell lung cancer patients treated with Iressa ZD , an inhibitor of epidermal growth factor. Acta Derm Venereol ; 84 — Oncologist ; 10 — Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol ; 6 — Dermatologic toxicity of chemotherapeutic agents. Semin Oncol ; 33 — Handfoot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis. Ann Dermatol Venereal ; Sl —
Effets cutanéo-muqueux indésirables des cytokines et des nouvelles molécules anticancéreuses
Mise au point. Hepatitis E virus infection: epidemiology and prevention. Key words : Hepatitis. Un seul clone, ET1. L'utilisation du clone ET1. Elles semblent, en revanche, stables dans l'azote liquide.